Kestra Investment Management LLC Buys 490 Shares of Eli Lilly and Company $LLY

Key Points

• Kestra Investment Management LLC increased its holdings in Eli Lilly and Company by 17.9%, acquiring an additional 490 shares in the first quarter, bringing its total to 3,221 shares valued at $2.66 million.
• Eli Lilly reported strong quarterly earnings, with an EPS of $6.31, exceeding estimates, and a year-over-year revenue increase of 37.6% to $15.56 billion.
• The company declared a quarterly dividend of $1.50 per share, set to be paid on September 10th, resulting in an annualized dividend yield of 0.8%.

Kestra Investment Management LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 3,221 shares of the company's stock after purchasing an additional 490 shares during the period. Kestra Investment Management LLC's holdings in Eli Lilly and Company were worth $2,660,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of LLY. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at $27,000. Citizens National Bank Trust Department lifted its stake in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $43,000. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.14% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, UBS Group dropped their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Trading Up 1.5%

NYSE LLY traded up $11.35 during trading hours on Tuesday, hitting $749.99. 2,983,536 shares of the company were exchanged, compared to its average volume of 4,436,129. The stock has a 50-day moving average price of $742.49 and a 200 day moving average price of $779.42. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $942.35. The stock has a market cap of $709.84 billion, a PE ratio of 49.02, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm posted $3.92 earnings per share. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.